INTRODUCTION
============

Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease with significant effects on patients' physical function and psychological status \[[@b1-pi-2019-06-05],[@b2-pi-2019-06-05]\]. It has become increasingly clear that psychological distress, such as depression or anxiety, is common in patients with including osteoarthritis \[[@b3-pi-2019-06-05]\], lupus \[[@b4-pi-2019-06-05]\] and rheumatic arthritis \[[@b5-pi-2019-06-05],[@b6-pi-2019-06-05]\]. Individuals with AS are more likely to be depressed than healthy individuals \[[@b7-pi-2019-06-05]\]. Depression is a chronic, prevalent condition, and is a leading cause of disability, affecting at least 120 million people worldwide \[[@b8-pi-2019-06-05]\]. In a population based study, doctor-diagnosed depression was found to be increased 1.81 and 1.49 fold respectively in women and men with AS \[[@b9-pi-2019-06-05]\]. It may be explained that AS is related to inflammation of depression because it is an inflammatory disease. Depressed AS patients tended to have poor long-term outcomes, including increased disease activity \[[@b10-pi-2019-06-05],[@b11-pi-2019-06-05]\], fatigue \[[@b12-pi-2019-06-05]\], decreased functionality \[[@b13-pi-2019-06-05]\], sleep disturbances \[[@b14-pi-2019-06-05]\], impaired quality of life \[[@b15-pi-2019-06-05]\], and high medical costs \[[@b16-pi-2019-06-05]\]. However, estimates of the prevalence of depression in AS patients varied across studies, from 3% \[[@b17-pi-2019-06-05]\] to 66% \[[@b18-pi-2019-06-05]\]. Such discrepancy could be explained by the differences in time frames when these studies were performed, study quality, or tools used for assessing depression. It is important for rheumatologists to establish reliable estimate of depression prevalence, in order to prevent, treat, and identify causes of depression in people with AS. Recent reviews have suggested that depression was highly prevalent among people with rheumatoid arthritis \[[@b19-pi-2019-06-05]\], osteoarthritis \[[@b3-pi-2019-06-05]\], and systemic lupus erythematosus \[[@b20-pi-2019-06-05]\]. Another systematic review found that the prevalence of neuropsychiatric damage in chronic rheumatic diseases such as lupus has been significantly increasing over the past 5 decades \[[@b21-pi-2019-06-05]\]. This finding is not surprising due to reduction in white matter and grey matter volumes in the very early stage of lupus \[[@b22-pi-2019-06-05]\]. As yet no systematic review has provided pooled prevalence estimates of depression in AS. Our goal was to fill this gap. We aimed to 1) describe the pooled prevalence of depression in people with AS; 2) compare depression prevalence and score in AS patients versus healthy controls; 3) explore the influence of study characteristics on prevalence estimates.

METHODS
=======

This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standard \[[@b23-pi-2019-06-05]\] and followed a predetermined registered protocol (PROSPERO: 42016052590).

Search strategy
---------------

The systematic literature search was conducted by two investigators independently through the PubMed, Embase, PsycINFO, Web of Science, Cochrane database library, China National Knowledge Infrastructure (CNKI), and Wanfang Database for pertinent studies published in English or Chinese from their inception to December 2016. The computer-based searches combined terms related to AS patients \[(depress\* or depress\* disorder\$ or affective disorder\$ or mood disorder\$ or adjustment disorder\$ or affective symptom\$ or dysthymi\*) AND (Ankylosing spondylitis or AS)\] ([Supplementary Material 1](#SD1-pi-2019-06-05){ref-type="supplementary-material"} in the online-only Data Supplement). The search was restricted to studies in humans. In addition, the reference lists of all identified relevant publications were reviewed. Finally, where published information was unclear or inadequate, we contacted the corresponding authors for more information.

Inclusion and exclusion criteria
--------------------------------

Studies were eligible if they met the following criteria: 1) observational studies (cross-sectional and prospective studies) and baseline data of randomized controlled trials with or without a comparison group without AS; 2) depression was measured by self-reported symptom scales, physician/clinician diagnosis, or structured clinical diagnostic interview. [Table 1](#t1-pi-2019-06-05){ref-type="table"} presented a full list of the eligible methods of detecting depression, alongside the numbers of participants assessed.

Studies were excluded if: 1) the study was not published as the full reports, such as case reports, commentaries, conference abstracts and letters to editors; 2) the study had a retrospective design; and 3) participants with depression at baseline were not excluded for the analysis.

Data extraction and quality assessment
--------------------------------------

Two trained investigators independently extracted data and assess quality of the studies included in this meta-analysis. Any disagreements in data extraction and quality assessment were resolved through discussion between the two investigators or adjudication with a third reviewer. We used a standardized form to record data on the authors, year of publication, country of study, participants, percentage of male participants, average age of participants, mean disease duration, criteria for detection of depression, and reported the prevalence or score of depression. If duplicate publications from the same study were identified, we would include the result with the largest number of individuals from the study. Wherever possible, we extracted the number affected and not affected by depression in each sample (using the authors' cut-off points for each outcome measure). If this was not available, we extracted the mean and standard deviation of the depression assessment scale. The investigators independently fulfilled the quality assessment using a modified version of the Newcastle-Ottawa Scale (NOS) in line with previous study \[[@b24-pi-2019-06-05]\]. Studies were judged to be at low risk of bias (≥3 points) or high risk of bias (\<3 points).

Outcome measures
----------------

The outcomes of interest were major depression diagnosed with a structured clinical assessment \[e.g., International Classification of Diseases (ICD)-10\] or depression assessed with a validated assessment tool or screening measure \[e.g., the Hospital Anxiety and Depression Scale (HADS), Beck Depression Inventory (BDI)\].

Statistical analyses
--------------------

Three analyses were undertaken. First, we pooled studies reporting the prevalence of depression in the AS sample using a random-effects models \[[@b25-pi-2019-06-05],[@b26-pi-2019-06-05]\]. Second, we used a pooled relative risk (RR) analysis with random-effect model. Third, we conducted a pooled standardized mean difference (SMD) analysis to investigate differences between those with and without AS. Statistical heterogeneity among studies was evaluated with I2 statistics with the values of 25%, 50%, and 75% respectively denoted cut-off points for low, moderate and high degrees of heterogeneity \[[@b27-pi-2019-06-05]\]. The influence of individual studies on the overall prevalence estimate was explored by serially excluding each study in a sensitivity analysis. Subgroup analyses were planned by overall study quality, sample size, country of origin and publication year to explore the sources of potential heterogeneity. Finally, we used Pearson's and Spearman's correlation analyses to assess the association between variables and prevalence of depression in people with AS. Potential publication bias was evaluated with a funnel plot \[[@b28-pi-2019-06-05]\] and the Egger's test \[[@b29-pi-2019-06-05]\]. Statistical analyses were all conducted on Statistical analyses were all conducted on STATA version 12.0 (Stata Corp, College Station, TX, USA).

RESULTS
=======

Search results
--------------

A total of 598 citations were identified. After removal of duplicates, titles and then abstracts were screened for potential eligibility. From this, 59 were potentially eligible and considered in the full-text review. Twenty-eight articles were excluded; thus, 31 records met the eligibility criteria and were included ([Figure 1](#f1-pi-2019-06-05){ref-type="fig"}), and a full reference list was shown in [Supplementary Material 2](#SD2-pi-2019-06-05){ref-type="supplementary-material"} (in the online-only Data Supplement). Inter-observer agreement (κ) between two investigators was 0.89.

Study characteristics
---------------------

[Table 1](#t1-pi-2019-06-05){ref-type="table"} and [2](#t2-pi-2019-06-05){ref-type="table"} presented the characteristics of the included studies. Thirty-one eligible studies consisted of 8,106 patients were reported. Nineteen studies were conducted in Asia, 7 studies in Europe, 3 studies in Africa, and 1 study in South America. The mean age was 39.2 years, and the mean percentage of males represented in the sample was 75.9%. In addition, the mean number of participants per study was 261, and the mean disease duration was 10.64 years. [Table 3](#t3-pi-2019-06-05){ref-type="table"} described the methods defined depression and the frequency of their use. Depression was assessed in 15 different ways. Thirteen studies assessed for depression using the HADS; three different cut-off points were presented, the most commonly used being 8. Five studies assessed for depression using the 21 Item-BDI, with four different thresholds were presented in the articles. Six used the Zung Self-rating Depression Scale (SDS), and three used other screening tools. Three assessed for depression using structured interview (e.g., ICD). [Supplementary Table 1](#SD3-pi-2019-06-05){ref-type="supplementary-material"} (in the online-only Data Supplement) summarized the quality assessment using a modified version of the NOS, which indicated that 1 study received 5 points, 3 studies received 4 points, 6 studies received 3 points, 18 studies received 2 points, and 3 studies received 1 point.

Prevalence of depression among AS patients
------------------------------------------

Prevalence estimates of depression varied from 3% to 66% in individual studies ([Table 1](#t1-pi-2019-06-05){ref-type="table"}). The overall pooled prevalence of depression was 35% (95% CI, 28--43%), with high betweenstudy heterogeneity (I^2^=98.8%, p\<0.001) ([Figure 2](#f2-pi-2019-06-05){ref-type="fig"}). [Table 3](#t3-pi-2019-06-05){ref-type="table"} presented the summary of meta-analyses and heterogeneity assessments. Prevalence estimates ranged from 9% (95% CI, 6--12%, I^2^=29.6%) according to the Hospital Anxiety and Depression Scale with thresholds of 11% to 49% (95% CI, 34--60%, I^2^=0%) for the 21-Item Beck Depression Inventory with a cutoff of 14 or more. Prevalence of major depressive disorder to be 13% (95% CI, 6--20%) according to the structured interview, with high heterogeneity (I^2^=98.4%).

Depression in AS versus non-AS cohorts
--------------------------------------

Eight studies included data on the prevalence estimates of depression for people with AS compared with those without AS. A pooled RR of 1.76 (95% CI: 1.21--2.55, n=3006) ([Figure 3](#f3-pi-2019-06-05){ref-type="fig"}). Seven studies (n=549) presented data comparing depression scores for people with AS compared with those without AS. The depression score (SMD=0.43, 95% CI: 0.19--0.67) was higher in AS patients than in controls ([Figure 4](#f4-pi-2019-06-05){ref-type="fig"}).

Sensitivity and subgroup analyses
---------------------------------

[Table 4](#t4-pi-2019-06-05){ref-type="table"} showed the prevalence estimates of depression according to each sensitivity and subgroup analysis, in comparison with the primary analysis. Sensitivity analyses found that the exclusion of studies with less sample representativeness tended to decrease depression prevalence estimates according to structured interview. The pooled SMD tended to decrease in AS patients verse controls by exclusion of studies only using male sample. The subgroup analyses were conducted by sample size, overall quality, publication year, and country of origin. The results showed that studies with sample size \<200 had higher depression prevalence estimates \[52% (95% CI, 44--60%) vs. 42% (95% CI, 39--45%)\] compared with primary analysis according to the HADS with thresholds of 8, and higher pooled RR \[3.72 (95% CI, 1.33--10.38) vs. 1.48 (95% CI, 1.06--2.06)\] in AS patients verse controls compared with the studies with sample size ≥200. When evaluated by Newcastle-Ottawa Scale (NOS), studies with lower total overall quality scores yielded higher depression estimates \[52% (95% CI, 41--63%) vs. 45% (95% CI, 28--62%)\] according to the HADS with thresholds of 8, and higher pooled RR \[3.72 (95% CI, 1.33--10.38) vs. 1.48 (95% CI, 1.06--2.06)\] compared with the studies with higher total overall quality scores. More recent publications and developing country tended to yield higher depression prevalence estimates according to the HADS with a cutoff of 8 or more. There was no particular trend or pattern in any other sensitivity analyses or subgroup analyses.

Associated study variables
--------------------------

Pearson's and Spearman's correlation analyses were employed to examine the relationship between variables including proportion of male participants, mean/medium age, mean/medium disease duration, sample size, representativeness, comparability, overall quality, country of origin, publication year, and the prevalence of depression. We found that small sample size (r=-0.45, p=0.016) and developing country (r=0.613, p=0.001) of the sample were significantly associated with increased depression prevalence ([Table 5](#t5-pi-2019-06-05){ref-type="table"}).

Assessment of publication bias
------------------------------

According to the Egger's test, assessment of publication bias suggested significant publication bias in studies reporting depression \[Egger: bias=7.87 (95% CI: 4.77--10.97), p\<0.001\] ([Supplementary Figure 1](#SD4-pi-2019-06-05){ref-type="supplementary-material"} in the online-only Data Supplement).

DISCUSSION
==========

This is the first systematic review and meta-analysis on the prevalence of depression in AS. This study indicated that depression were more prevalent in AS patients than in controls. In this study, the pooled prevalence of depression in AS patients is 35% and higher than other chronic medical illnesses such as asthma (27%) \[[@b30-pi-2019-06-05]\], chronic obstructive lung disease (24.6%) \[[@b31-pi-2019-06-05]\], lupus (24%) \[[@b20-pi-2019-06-05]\] and rheumatoid arthritis (15%) \[[@b32-pi-2019-06-05]\]. This meta-analysis also revealed that small sample size and developing country of the studies conducted were significantly associated with increased depression prevalence, which might be explained that small studies often led to high prevalence estimates, and people with low socio-economic status (SES) in developing country was associated with increased susceptibility to depression \[[@b19-pi-2019-06-05]\].

Our sensitivity analyses indicated that depression prevalence estimates were relatively stable. Apart from the measurement tool used to ascertain depression, study quality and study population had impacts on the estimates detected. Our subgroup analyses found that variation in study sample size contributed importantly to the observed heterogeneity in the data. Studies with sample size \<200 had higher depression estimates according to the HADS with a cutoff of 8 or more. Study quality might be a further explanation for the variance in prevalence estimates. Studies with lower total overall quality scores yielded higher depression estimates using the HADS with thresholds of 8.

We used rigorous methods to conduct the review and a reproducible, structured approach to data extraction and synthesis. The gold standard method was diagnostic interviews using ICD criteria, which were often time consuming and expensive, therefore, it was not ideal for investigating patients in a busy hospital environment \[[@b33-pi-2019-06-05]\]. Alternatively, self-report screening tools might be used. Although such self-reported questionnaires were quick and easy to complete and cheaper to use than diagnostic interviews in psychiatric practices, the different scales and cutoffs used to define the presence or the absence of depression could vary \[[@b33-pi-2019-06-05]\]. Such nature would lead to information bias and methodological heterogeneity when combining these data in a meta-analysis. It indicated that the rheumatologists should report prevalence at conventional cut-points, and screen for depression among AS patients according to the social and cultural contexts of the rheumatologists and patients in clinical practice.

However, this study still had some limitations. Firstly, a substantial amount of the heterogeneity among the studies remained unexplained by the variables examined. And there was inadequate data to conduct subgroup analyses according to variables of interest such as gender, disease duration and impact of age. A better understanding of social and cultural contexts of AS patients may help elucidate some of the root causes of depressive symptoms. Secondly, the data were derived from studies that used different designs and involved different groups of patients (e.g., different countries and years of publication), which might result in heterogeneity among the studies. Thirdly, the analysis relied on aggregated published data, which might result in potential publication bias.

CONCLUSIONS
===========

One-third of people with AS experienced symptoms of depression. Depression was more prevalent in AS patients than in controls. Further research is needed to identify effective strategies for preventing and treating depression among AS patients.
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###### 

Overview of prevalence studies of depression in AS patients

  Study ID                Country     Participants   Men, %   Age, mean±SD/median (range), years   Disease duration, mean±SD/median (range), years   Criteria for detection of depression (cutoff)   Prevalence, %   NOS
  ----------------------- ----------- -------------- -------- ------------------------------------ ------------------------------------------------- ----------------------------------------------- --------------- -----
  Aissaoui 2012           Morocco     110            68.2     38.52±12.62                          9 (0--40)                                         HADS (≥8)                                       55.5            2
  Altan 2003              NS          63             NS       NS                                   NS                                                HADS (≥8)                                       33.3            1
  Anyfanti 2012           Greece      44             68.8     NS                                   NS                                                Zung SDS (≥50)                                  18.2            1
  Arisoy 2013             Turkey      9              88.9     39.4±10.1                            10.6±7.6                                          HADS (≥7)                                       33              2
  Aydin 2016              Turkey      37             62.3     34.67±7.90                           7.16±2.49                                         HADS (≥8)                                       48.5            3
  Baysal 2011             Turkey      243            86.4     34.65±10.36                          6.02±6.60                                         HADS (≥7)                                       39.8            3
  Cakar 2007              Turkey      52             100      32.85±12.11                          9.09±7.36                                         21 Item-BDI (≥14/25)                            50/13.5         2
  Cooksey 2015            UK          348            77.0     56.0±13.0                            22.0±15.0                                         HADS (≥11)                                      7.5             4
  Demir 2013              Turkey      22             0        39.34±6.28                           3.3±2.6                                           21 Item-BDI (≥14)                               45.5            2
  Dhakad 2015             India       100            100      34.42±9.78                           4.84±0.06                                         HADS (≥8)                                       66              2
  Durmus 2015             Turkey      80             63.8     39.33±10.98                          10.88±10.08                                       21 Item-BDI (\>17)                              22.5            2
  Ertenli 2012            Turkey      16             81.2     36.4 ±10.3                           12.8±9.5                                          HADS (≥8)                                       43.8            2
  Ersözlü-Bozkirli 2015   Turkey      29             79.3     34.4±10.3                            4.1±6.2                                           21 Item-BDI (≥30)                               37.9            2
  Fallahi 2014            Iran        163            79.1     37.74±9.88                           14.49±8.47                                        Structured interview                            29.4            2
  Günaydin 2009           Turkey      62             83.9     39.6±10.3                            10.3±7.9                                          Zung SDS (≥50)                                  27.4            2
  Hakkou 2011             Morocco     110            68.2     38.5±12.6                            10.3±8.1                                          HADS (≥8)                                       55.5            2
  Healey 2009             UK          612            71.6     50.8±12.2                            10.3±8.1                                          HADS (≥8)                                       32.4            5
  Hyphantis 2013          Greece      55             85.5     42.9±10.9                            15.3±11.5                                         PHQ-9 (≥5/10)                                   40.7/14.8       2
  Jiang 2015              China       683            80.4     27.33±8.67                           6.47±6.47                                         Zung SDS (NS)                                   64              4
  Li 2012                 China       314            74.5     27.65±8.34                           6.07±4.90                                         Zung SDS (≥50)                                  41.4            4
  Lian 2003               China       60             78.0     36.0±12.0                            \>5 years (68%)                                   Zung SDS (≥41)                                  43.3            2
  Martindale 2006         UK          89             83.1     50 (18--77)                          18 (12--29)                                       HADS (≥11)                                      12.4            3
  Meesters 2014           Sweden      1,738          65       54.5±14.3                            NS                                                Structured interview, ICD-10                    10              3
  Rodríguez-Lozano 2012   Spain       190            75       48.4±11.7                            20.2±11                                           HADS (≥11)                                      11              2
  Rostom 2013             Morocco     110            100      38.5±12.6                            9 (0--40)                                         HADS (≥8)                                       55.5            3
  Schneeberger 2015       Argentina   64             89.1     44 (33--53)                          17 (10.3--25)                                     CES-D (≥16)                                     39.1            2
  Shen 2016               China       2,331          64.9     36.50 (27.25--48.18)                 NS                                                Structured interview, ICD-9                     3.1             3
  Xu 2016                 China       103            75.7     32.9±10.7                            NS                                                Zung SDS (≥53)                                  36.9            2

NS: not stated, ID: identification, SD: standard deviation, AS: ankylosing spondylitis, HADS: Hospital Anxiety and Depression Scale, SDS: Self-rating Depression Scale, BDI: Beck Depression Inventory, PHQ: Patient Health Questionnaire, ICD: International Classification of Diseases, CES-D: Centre for Epidemiological Studies Depression Scale, NOS: Newcastle-Ottawa Scale

###### 

Overview of studies of depression in AS patients and control group

  Study ID            Country     Study design      Participants                \% of male in AS group   \% of male in control group   Mean/median age (years) in AS group±SD (range)   Mean/median age (years) in control group±SD (range)   Mean disease duration of AS (years)±SD   Depression measures   NOS
  ------------------- ----------- ----------------- --------------------------- ------------------------ ----------------------------- ------------------------------------------------ ----------------------------------------------------- ---------------------------------------- --------------------- -----
  Altan 2003          NS          Case control      63 AS and 60 control        NS                       NS                            NS                                               NS                                                    NS                                       HADS                  1
  Baysal 2011         Turkey      Cross-sectional   243 AS and 118 control      86.4                     78.8                          34.65±10.36                                      36.53±9.26                                            6.02±6.60                                HADS                  3
  Demir 2013          Turkey      Case control      22 AS and 27 control        0                        0                             39.34±6.28                                       37.58±9.58                                            3.3±2.6                                  21 Item-BDI           2
  Dhakad 2015         India       Case control      100 AS and 100 control      100                      100                           34.42±9.78                                       36.39±8.07                                            4.84±0.06                                HADS                  2
  Dincer 2007         Turkey      Case control      68 AS and 45 control        100                      100                           32.9±11.0                                        30.1±6.24                                             NS                                       21 Item-BDI           1
  Durmus 2015         Turkey      Case control      80 AS and 80 control        63.8                     71.2                          39.33±10.98                                      36.41±10.84                                           10.88±10.08                              21 Item-BDI           2
  Ortancil 2010       Turkey      Case control      29 AS and 20 control        69                       60                            42.0±9.7                                         38.2±12.5                                             9.4±7.7                                  SCL-90-R              2
  Ozkorumak 2011      Turkey      Case control      43 AS and 43 control        100                      100                           36.25±8.76                                       36.53±6.54                                            7.51±7.22                                21 Item-BDI           2
  Schneeberger 2015   Argentina   Case control      64 AS and 95 control        89.1                     89.5                          44 (33--53)                                      40 (32--53)                                           17 (10.3--25)                            CES-D                 2
  Shen 2016           China       Cohort            2,331 AS and 9324 control   64.9                     64.9                          36.50 (27.25--48.18)                             36.50 (27.25--48.18)                                  NS                                       ICD-9                 3
  Xu 2016             China       Cross-sectional   103 AS and 121 control      75.7                     60.3                          32.9±10.7                                        37.0±12.5                                             NS                                       Zung SDS              2

NS: not stated, ID: identification, SD: standard deviation, AS: ankylosing spondylitis, HADS: Hospital Anxiety and Depression Scale, BDI: Beck Depression Inventory, SCL-90-R: Symptoms Checklist-90-Revised, CES-D: Centre for Epidemiological Studies Depression Scale, ICD: International Classification of Diseases, SDS: Self-rating Depression Scale, NOS: Newcastle-Ottawa Scale

###### 

Methods of detecting depression and summary of prevalence and heterogeneity findings

  Tool                               Definition/cutoff   No. of studies   No. of participants   Prevalence, % (95% CI)   Heterogeneity I^2^, %
  ---------------------------------- ------------------- ---------------- --------------------- ------------------------ -----------------------
  HADS                               ≥7                  2                252                   40 (34--46)              0
                                     ≥8                  8                1,158                 42 (39--45)              91.1
                                     ≥11                 3                627                   9 (6--12)                29.6
  21 Item-BDI                        ≥14                 2                74                    49 (34--60)              0
                                     \>17                1                80                    22 (13--32)              \-
                                     ≥25                 1                52                    14 (4--23)               \-
                                     ≥30                 1                29                    38 (20--56)              \-
  Zung SDS                           \>41                1                60                    43 (31--56)              \-
                                     ≥50                 3                420                   30 (15--44)              87.0
                                     ≥53                 1                103                   37 (28--46)              \-
                                     NS                  1                683                   64 (60--68)              \-
  Structured interview (e.g., ICD)                       3                4,232                 13 (6--20)               98.4
   CES-D                             ≥16                 1                64                    39 (27--51)              \-
   PHQ-9                             ≥5                  1                55                    41 (28--54)              \-
                                     ≥10                 1                55                    15 (5--24)               \-

NS: not stated, HADS: Hospital Anxiety and Depression Scale, BDI: Beck Depression Inventory, SDS: Self-rating Depression Scale, ICD: International Classification of Diseases, CES-D: Centre for Epidemiological Studies Depression Scale, PHQ: Patient Health Questionnaire

###### 

Impact of study characteristics on prevalence estimates for depression in AS: sensitivity and subgroup analyses

                                                                                        Prevalence estimates for depression in AS patients   Prevalence of depression in AS patients versus control group (RR)   Scores of depression in AS patients versus control group (SMD)                                                     
  ------------------------------------------------------------------------------------- ---------------------------------------------------- ------------------------------------------------------------------- ---------------------------------------------------------------- ------------------------ ------------------------ --------------------
  Primary analysis                                                                      42 (39, 45)                                          9 (6, 12)                                                           30 (15, 44)                                                      13 (6, 20)               1.76 (1.21, 2.55)        0.43 (0.19, 0.67)
  I^2^=91.1%                                                                            I^2^=29.6%                                           I^2^=87.0%                                                          I^2^=98.4%                                                       I^2^=75.8%               I^2^=64.7%               
  8 studies                                                                             3 studies                                            3 studies                                                           3 studies                                                        8 studies                7 studies                
  1,158 AS                                                                              627 AS                                               420 AS                                                              4,232 AS                                                         3,006 AS/9,925 control   549 AS/428 control       
  Sensitivity analyses                                                                                                                                                                                                                                                                                                              
   Excluding studies with less sample representativeness                                \-                                                   \-                                                                  \-                                                               7 (0, 13)                \-                       \-
                                                                                                                                                                                                                 I^2^=98.6%                                                                                                         
                                                                                                                                                                                                                 2 studies                                                                                                          
                                                                                                                                                                                                                 4,069 AS                                                                                                           
   Excluding studies with less comparable respondent and non-respondent comparability   45 (28, 62)                                          9 (5, 13)                                                           \-                                                               \-                       \-                       \-
  I^2^=91.3%                                                                            I^2^=40.9%                                                                                                                                                                                                                                  
  3 studies                                                                             2 studies                                                                                                                                                                                                                                   
  759 AS                                                                                437 AS                                                                                                                                                                                                                                      
   Excluding studies only using male sample                                             45 (34, 56)                                          9 (6, 12)                                                           30 (15, 44)                                                      13 (6, 20)               1.85 (1.24, 2.75)        0.28 (0.13, 0.43)
  I^2^=87.0%                                                                            I^2^=29.6%                                           I^2^=87.0%                                                          I^2^=98.4%                                                       I^2^=64%                 I^2^=0%                  
  6 studies                                                                             3 studies                                            3 studies                                                           3 studies                                                        7 studies                5 studies                
  948 AS                                                                                627 AS                                               358 AS                                                              4,232 AS                                                         2,906 AS/9,825 control   438 AS/340 control       
  Subgroup analyses                                                                                                                                                                                                                                                                                                                 
   Sample size                                                                                                                                                                                                                                                                                                                      
    \<200                                                                               52 (44, 60)                                          11 (8, 15)                                                          23 (14, 32)                                                      \-                       3.72 (1.33, 10.38)       0.49 (0.22, 0.75)
                                                                                        I^2^=70.0%                                           I^2^=0%                                                             I^2^=22.1%                                                                                I^2^=87%                 I^2^=59%
                                                                                        7 studies                                            2 studies                                                           2 studies                                                                                 6 studies                6 studies
                                                                                        546 AS                                               279 AS                                                              108 AS                                                                                    432 AS/483 control       306 AS/310 control
    ≥200                                                                                \-                                                   \-                                                                  \-                                                               7 (0, 13)                1.48 (1.06, 2.06)        \-
                                                                                                                                                                                                                                                                                  I^2^=98.6%               I^2^=40%                 
                                                                                                                                                                                                                                                                                  2 studies                2 studies                
                                                                                                                                                                                                                                                                                  4,069 AS                 2574 AS/9442 control     
  Overall quality                                                                                                                                                                                                                                                                                                                   
   \<3 points (low quality)                                                             52 (41, 63)                                          \-                                                                  23 (14, 32)                                                      \-                       3.72 (1.33, 10.38)       0.49 (0.22, 0.75)
                                                                                        I^2^=79.4%                                                                                                               I^2^=22.1%                                                                                I^2^=87%                 I^2^=59%
                                                                                        5 studies                                                                                                                2 studies                                                                                 6 studies                6 studies
                                                                                        399 AS                                                                                                                   108 AS                                                                                    432 AS/483 control       306 AS/310 control
   ≥3 points (high quality)                                                             45 (28, 62)                                          9 (5, 13)                                                           \-                                                               7 (0, 13)                1.48 (1.06, 2.06)        \-
                                                                                        I^2^=91.3%                                           I^2^=40.9%                                                                                                                           I^2^=98.6%               I^2^=40%                 
                                                                                        3 studies                                            2 studies                                                                                                                            2 studies                2 studies                
                                                                                        759 AS                                               437 AS                                                                                                                               4,069 AS                 2,574 AS/9,442 control   
  Publication year                                                                                                                                                                                                                                                                                                                  
   2000s                                                                                32 (29, 32)                                          \-                                                                  \-                                                               \-                       \-                       \-
  I^2^=0%                                                                                                                                                                                                                                                                                                                           
  2 studies                                                                                                                                                                                                                                                                                                                         
  675 AS                                                                                                                                                                                                                                                                                                                            
   2010--                                                                               57 (52, 62)                                          9 (5, 12)                                                           30 (8, 53)                                                       7 (0, 13)                2.98 (1.47, 6.06)        0.43 (0.15, 0.70)
  I^2^=18.2%                                                                            I^2^=41.7%                                           I^2^=92.3%                                                          I^2^=98.6%                                                       I^2^=88%                 I^2^=70%                 
  6 studies                                                                             2 studies                                            2 studies                                                           2 studies                                                        7 studies                6 studies                
  483 AS                                                                                538 AS                                               358 AS                                                              4,069 AS                                                         2,943 AS/9,865 control   481 AS/383 control       
  Country of origin                                                                                                                                                                                                                                                                                                                 
   Asia                                                                                 55 (41, 70)                                          \-                                                                  35 (22, 49)                                                      16 (-10, 12)             3.27 (1.41, 7.58)        0.44 (0.15, 0.72)
  I^2^=62.0%                                                                                                                                 I^2^=79.7%                                                          I^2^=98.1%                                                       I^2^=90%                 I^2^=70%                 
  3 studies                                                                                                                                  2 studies                                                           2 studies                                                        6 studies                6 studies                
  153 AS                                                                                                                                     376 AS                                                              2,494 AS                                                         2,879 AS/9,770 control   485 AS/333 control       
   Europe                                                                               \-                                                   9 (6, 12)                                                           \-                                                               \-                       \-                       \-
                                                                                        I^2^=29.6%                                                                                                                                                                                                                                  
                                                                                        3 studies                                                                                                                                                                                                                                   
                                                                                        627 AS                                                                                                                                                                                                                                      
   Africa                                                                               56 (50, 61)                                          \-                                                                  \-                                                               \-                       \-                       \-
  I^2^=0%                                                                                                                                                                                                                                                                                                                           
  3 studies                                                                                                                                                                                                                                                                                                                         
  330 AS                                                                                                                                                                                                                                                                                                                            

AS: ankylosing spondylitis, HADS: Hospital Anxiety and Depression Scale, SDS: Self-rating Depression Scale, RR: relative risk, SMD: standardized mean difference

###### 

Pearson's and Spearmen's correlation between study characteristics and prevalence estimates

  Study characteristic                 Depression prevalence estimate                                                            
  ------------------------------------ -------------------------------- -------------------------------------------------------- -------
  Male, %                              27                               0.153                                                    0.445
  Mean/medium age, year                27                               -0.054                                                   0.790
  Mean/medium disease duration, year   27                               -0.035                                                   0.861
  Sample size                          28                               -0.450^[\*](#tfn1-pi-2019-06-05){ref-type="table-fn"}^   0.016
  Representativeness                   28                               -0.215                                                   0.272
  Comparability                        28                               -0.066                                                   0.737
  Overall quality                      28                               -0.055                                                   0.780
  Country of origin                    27                               -0.613^[†](#tfn2-pi-2019-06-05){ref-type="table-fn"}^    0.001
  Publication year                     28                               0.108                                                    0.585

p\<0.05,

p\<0.01
